SRT1720 | 1001645-58-4

SRT1720 Properties

Melting point	>205°C (dec.)
Density	1.58
storage temp.	= -70C
solubility	Soluble in DMSO (>25 mg/ml)
form	Liquid
color	White
Stability	Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.

SAFETY

Risk and Safety Statements

Symbol(GHS)	GHS07
Signal word	Warning
Hazard statements	H302-H315-H319-H335
Precautionary statements	P261-P280-P301+P312-P302+P352-P305+P351+P338

SRT1720 price More Price(39)

Manufacturer	Product number	Product description	CAS number	Packaging	Price	Updated	Buy
Sigma-Aldrich	5.30748	InSolution SRT1720, HCl - CAS 1001645-58-4 - Calbiochem A 25 mM (10 mg/650 μl) sterile-filtered solution of SRT1720, HCl in DMSO.	1001645-58-4	10MG	$264	2024-03-01	Buy
Cayman Chemical	10011020	SRT 1720 (hydrochloride) ≥98%	1001645-58-4	1mg	$39	2024-03-01	Buy
Cayman Chemical	10011020	SRT 1720 (hydrochloride) ≥98%	1001645-58-4	5mg	$126	2024-03-01	Buy
Cayman Chemical	10011020	SRT 1720 (hydrochloride) ≥98%	1001645-58-4	10mg	$210	2024-03-01	Buy
Cayman Chemical	10011020	SRT 1720 (hydrochloride) ≥98%	1001645-58-4	50mg	$847	2024-03-01	Buy

Product number	Packaging	Price	Buy
5.30748	10MG	$264	Buy
10011020	1mg	$39	Buy
10011020	5mg	$126	Buy
10011020	10mg	$210	Buy
10011020	50mg	$847	Buy

SRT1720 Chemical Properties,Uses,Production

Description

SRT1720 is a selective SIRT1 activator with EC50 of 0.16 μM in a cell-free assay, but is >230-fold less potent for SIRT2 and SIRT3.

In vitro

The maximum activation ratio of SRT1720 versus the closest sirtuin homologues, SIRT2 (EC1.5 = 37 μM) and SIRT3 (EC1.5 > 300 μM) is up to 781%. SRT1720 binds to the SIRT1 enzyme-peptide substrate complex at an allosteric site amino-terminal to the catalytic domain and lower the Michaelis constant for acetylated substrates. SRT1720 could reduce fed glucose levels. Glucose excursion during an intraperitoneal glucose tolerance test is also significantly reduced in the SRT1720 group, and comparable to rosiglitazone, a PPARγ activator that has been used to treat type 2 diabetes. SRT1720 does not have an effect on fasting glucose in chow-fed mice, revealing that pharmacological SIRT1 activation is unlikely to induce hypoglycaemia. SRT1720 significantly reduces the hyperinsulinaemia after 4 weeks, partially normalizing increased insulin levels similar to rosiglitazone treatment. SRT1720 treatment increases mitochondrial capacity by 15% in gastrocnemius muscle as measured by citrate synthase activity. Higher concentrations of SRT1720 (15 μM) induces a modest (10-20%) decrease in normal cell viability. SRT1720 also significantly inhibits VEGF-dependent MM cell migration.

In vivo

In DIO mice SRT1720 mimics several of the effects observed after calorie restriction including improved insulin sensitivity, normalized glucose and insulin levels, and increased mitochondrial capacity. In addition, in diet-induced obese and genetically obese mice, SRT1720 improves insulin sensitivity, lower plasma glucose, and increase mitochondrial capacity. Thus, SRT1720 is a promising new therapeutic agent for treating diseases of ageing such as type 2 diabetes. Consistent with improved glucose tolerance, the glucose infusion rate required to maintain euglycaemia is approximately 35% higher in SRT1720-treated fa/fa rats, and the total glucose disposal rate is increased by approximately 20%. SRT1720 also prevents multiple myeloma tumor growth. SRT1720 increases the cytotoxic activity of bortezomib or dexamethasone.

References

http://www.selleckchem.com/products/SRT1720.html

Description

SRT1720 (1001645-58-4) is a SIRT1 activator (EC1.5 = 0.16 μM, max activation = 781%).1 It reduced glucose levels and hyperinsulinemia in DIO, Lepob/ob mice and Zucker fa/fa rats.? SRT1720 enhanced endurance running and protected against diet-induced obesity and insulin resistance via enhancement of oxidative metabolism in skeletal muscle, liver, and brown adipose tissue.2 It induced mitochondrial biogenesis in oxidant-induced renal proximal tube cell injury.3 SRT1720 repressed circadian clock gene expression and decreased H3 K9/K14 acetylation in a time-specific manner.4 It attenuated angiotensin II-induced atherosclerosis by inhibiting the vascular inflammatory response.5

Uses

SRT1720 acts as a therapeutic in the treatment of type 2 diabetes. It modulates calories and contributes to glucose homeostasis and insulin sensitivity.

General Description

An enhanced aqueous soluble version of SRT1720 (Cat. No. 567860).

Biochem/physiol Actions

Cell permeable: yes

target

SIRT1

References

Milne et al. (2007), Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes; Nature 450 712 Feige et al. (2008), Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation; Cell Metab. 8 347 Funk et al. (2010), SRT1720 induces mitochondrial biogenesis and rescues mitochondrial function after oxidant injury in renal proximal tubule cells; J. Pharmacol. Exp. Ther. 333 593 Bellet et al. (2013), Pharmacological modulation of circadian rhythms by synthetic activators of the deacetylase SIRT1; Proc. Natl. Acad. Sci. USA 110 3333 Chen et al. (2015), The Sirt1 activator SRT1720 attenuates angiotensin II-induced atherosclerosis in apoE-/- mice through inhibiting vascular inflammatory response; Biochem. Biophys. Res. Commun. 465 732

SRT1720 Preparation Products And Raw materials

Raw materials

Preparation Products

SRT1720 Suppliers

Global( 166)Suppliers

Supplier	Tel	Email	Country	ProdList	Advantage
Capot Chemical Co.,Ltd.	571-85586718 +8613336195806	sales@capotchem.com	China	29797	60
Hangzhou FandaChem Co.,Ltd.	008657128800458; +8615858145714	fandachem@gmail.com	China	9339	55
ATK CHEMICAL COMPANY LIMITED	+undefined-21-51877795	ivan@atkchemical.com	China	32715	60
career henan chemical co	+86-0371-86658258	sales@coreychem.com	China	29914	58
Biochempartner	0086-13720134139	candy@biochempartner.com	CHINA	967	58
BOC Sciences	+1-631-485-4226	inquiry@bocsci.com	United States	19553	58
Chongqing Chemdad Co., Ltd	+86-023-6139-8061 +86-86-13650506873	sales@chemdad.com	China	39916	58
Alchem Pharmtech,Inc.	8485655694	sales@alchempharmtech.com	United States	63711	58
CONIER CHEM AND PHARMA LIMITED	+8618523575427	sales@conier.com	China	49391	58
TargetMol Chemicals Inc.	+1-781-999-5354 +1-00000000000	marketing@targetmol.com	United States	19892	58

Supplier	Advantage
Capot Chemical Co.,Ltd.	60
Hangzhou FandaChem Co.,Ltd.	55
ATK CHEMICAL COMPANY LIMITED	60
career henan chemical co	58
Biochempartner	58
BOC Sciences	58
Chongqing Chemdad Co., Ltd	58
Alchem Pharmtech,Inc.	58
CONIER CHEM AND PHARMA LIMITED	58
TargetMol Chemicals Inc.	58

View Lastest Price from SRT1720 manufacturers

Image	Update time	Product	Price	Min. Order	Purity	Supply Ability	Manufacturer
	2019-07-06	SRT1720 1001645-58-4	US $1000.00 / KG	1G	99%	100kg	Career Henan Chemical Co

SRT1720
1001645-58-4
US $1000.00 / KG
99%
Career Henan Chemical Co

SRT1720 Spectrum

SRT1720(1001645-58-4)¹HNMR

1001645-58-4(SRT1720)Related Search:

N-[2-[3-(1-Piperazinylmethyl)imidazo[2,1-b]thiazol-6-yl]phenyl]-2-quinoxalinecarboxamide N-(5-((5-(4-Acetylpiperazine-1-carbonyl)-4-methoxy-2-methylphenyl)thio)thiazol-2-yl)-4-(((3,3-dimethylbutan-2-yl)amino)methyl)benzamide N-[(1R)-1-(Aminomethyl)-2-[(3S)-tetrahydro-2H-pyran-3-yl]ethyl]-N-methylcarbamic acid tert-butyl ester MK-8617 N,N'-[1,2-Ethanediylbis(oxy-2,1-phenylene)]bis[N-(carboxymethyl)glycine 1,1'-bis[2-(octyloxy)ethyl] ester

N-BOC-cis-4-fluoro-L-proline MG-132 N-(8-Benzyl-8-azabicyclo[3.2.1]oct-3-yl-exo)-2-methylpropanamide N-Boc-3-piperidineacetic acid N-(Methoxymethyl)-N-(trimethylsilylmethyl)benzylamine

N-Boc-exo-3-aminotropane N-Boc-endo-3-aminotropane N-(3-HYDROXYPROPYL)ETHYLENEDIAMINE SIRTINOL Resveratrol

5-Aza-2'-deoxycytidine 6-CHLORO-2,3,4,9-TETRAHYDRO-1H-CARBAZOLE-1-CARBOXAMIDE Olaparib

1of4

N-(2-(3-(piperazin-1-ylMethyl)iMidazo[2,1-b]thiazol-6-yl)phenyl)quinoxaline-2-carboxaMide hydrochloride SRT1720 N-[2-[3-(1-Piperazinylmethyl)imidazo[2,1-b]thiazol-6-yl]phenyl]-2-quinoxalinecarboxamide hydrochloride SRT1720HCL SRT 1720 (Hydrochloride) N-[2-[3-(1-Piperazinylmethyl)imidazo[2,1-b]thiazol-6-yl]phenyl]-2-quinoxalinecarboxamide hydrochloride SRT 1720 SRT-1720 xhydrochloride SRT1720 hydrochloride, >=98% SRT 1720 tetrahydrochloride SRT1720;SRT-1720 N-(2-(3-(Piperazin-1-ylmethyl)imidazo[2,1-b]thiazol-6-yl)phenyl)quinoxaline-2-carboxamide hydr CAY10559 CAY-10559 SIRT 1933 SIRT-1933 SIRT1933. SRT-1720 HCl, SRT-1720 hydrochloride SRT-1720 HCL, SRT-1720 HYDROCHLORIDE; SRT1720; SRT-1720; SRT 1720; CAY10559; CAY-10559; CAY 10559; SIRT-1933; SIRT 1933; SIRT1933. N-[2-[3-(piperazin-1-ylmethyl)imidazo[2,1-b][1,3]thiazol-6-yl]phenyl]quinoxaline-2-carboxamide,hydrochloride STR1720 CS-233 SRT1720 USP/EP/BP SRT1720 HCL (CAY-10559) Emsorb 2505 Liposorb S-20 Sorbon S 60 Span 55 CAY 10559 N-(2-(3-(Piperazin-1-ylmethyl)imidazo[2,1-b]thiazol-6-yl)phenyl)quinoxaline-2-carboxamide xhydrochloride SRT-1720 HCl SRT1720 HCl SRT-1720 hydrochloride,SRT1720 hydrochloride 1001645-58-4 C25H23N7OSHCl C25H24ClN7OS Inhibitor Inhibitors